Stock Track | I-MAB Surges 5.70% Pre-Market on Board Appointments and R&D Committee Formation

Stock Track

Aug 25, 2025

Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, soared 5.70% in pre-market trading on Monday. The surge comes on the heels of the company's announcement of significant changes to its leadership structure and research focus.

I-MAB revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This strategic move is aimed at accelerating innovation and long-term growth for the company.

Additionally, I-MAB announced the expansion of its Scientific Advisory Board with the appointment of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These appointments are viewed as a significant step forward for I-MAB as it progresses with the development of givastomig, its potential best-in-class bispecific antibody for gastric cancers. The market's positive reaction suggests investors are optimistic about the company's enhanced leadership and renewed focus on research and development, which could potentially drive future growth and innovation in its immuno-oncology pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184158025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184158025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184158025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184158025","market":"us","top_or_hot":-1,"title":"Stock Track | I-MAB Surges 5.70% Pre-Market on Board Appointments and R&D Committee Formation","media":"Stock Track","content":"<p>Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, soared 5.70% in pre-market trading on Monday. The surge comes on the heels of the company's announcement of significant changes to its leadership structure and research focus.</p>\n\n<p>I-MAB revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This strategic move is aimed at accelerating innovation and long-term growth for the company.</p>\n\n<p>Additionally, I-MAB announced the expansion of its Scientific Advisory Board with the appointment of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These appointments are viewed as a significant step forward for I-MAB as it progresses with the development of givastomig, its potential best-in-class bispecific antibody for gastric cancers. The market's positive reaction suggests investors are optimistic about the company's enhanced leadership and renewed focus on research and development, which could potentially drive future growth and innovation in its immuno-oncology pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | I-MAB Surges 5.70% Pre-Market on Board Appointments and R&D Committee Formation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | I-MAB Surges 5.70% Pre-Market on Board Appointments and R&D Committee Formation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-25 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, soared 5.70% in pre-market trading on Monday. The surge comes on the heels of the company's announcement of significant changes to its leadership structure and research focus.</p>\n\n<p>I-MAB revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This strategic move is aimed at accelerating innovation and long-term growth for the company.</p>\n\n<p>Additionally, I-MAB announced the expansion of its Scientific Advisory Board with the appointment of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These appointments are viewed as a significant step forward for I-MAB as it progresses with the development of givastomig, its potential best-in-class bispecific antibody for gastric cancers. The market's positive reaction suggests investors are optimistic about the company's enhanced leadership and renewed focus on research and development, which could potentially drive future growth and innovation in its immuno-oncology pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1184158025","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184158025","pubTimestamp":1756124916,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, soared 5.70% in pre-market trading on Monday. The surge comes on the heels of the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"个股追踪|天境生物盘前大涨5.70%董事会任命及研发委员会组建","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":1},"content_text":"Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, soared 5.70% in pre-market trading on Monday. The surge comes on the heels of the company's announcement of significant changes to its leadership structure and research focus.\nI-MAB revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This strategic move is aimed at accelerating innovation and long-term growth for the company.\nAdditionally, I-MAB announced the expansion of its Scientific Advisory Board with the appointment of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These appointments are viewed as a significant step forward for I-MAB as it progresses with the development of givastomig, its potential best-in-class bispecific antibody for gastric cancers. The market's positive reaction suggests investors are optimistic about the company's enhanced leadership and renewed focus on research and development, which could potentially drive future growth and innovation in its immuno-oncology pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}